Optimising Heart Failure Therapies in the Acute Setting by Arrigo, Mattia et al.








Optimising Heart Failure Therapies in the Acute Setting
Arrigo, Mattia ; Nijst, Petra ; Rudiger, Alain
Abstract: Acute heart failure (AHF) is a life-threatening condition requiring immediate treatment. The
initial therapy should take into account the clinical presentation, pathophysiology at play, precipitating
factors and underlying cardiac pathology. Particular attention should be given to polymorbidity and
the avoidance of potential iatrogenic harm. Patient preferences and ethical issues should be integrated
into the treatment plan at an early stage. The average survival of AHF patients is 2 years and the
most vulnerable period is the 3-month time window directly after discharge. Reducing both persistent
subclinical congestion and underutilisation of disease-modifying heart failure therapies as well as ensuring
optimal transitions of care after hospital discharge are essential in improving outcomes for AHF patients.
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Treatment
Heart failure is a clinical syndrome induced by cardiac abnormalities 
resulting in reduced cardiac output and/or elevated intra-cardiac end-
diastolic pressures and causing symptoms that are often accompanied 
by typical physical signs.1 Demographic changes, improved treatment of 
several acute cardiac disorders, such myocardial infarction, arrhythmia 
and congenital heart disease, and increased long-term survival of 
patients with reduced left ventricular systolic function have led to a 
dramatic increase in the number of patients living with heart failure. 
Acute heart failure (AHF) is defined as new-onset or worsening of 
symptoms and signs of heart failure.1 AHF is the most frequent cause 
of unplanned hospital admission in patients aged 65 years or older 
and is characterised by significant in-hospital mortality and frequent 
readmissions.2,3 Outcomes of AHF remain globally poor.4,5 Independent 
of ejection fraction, the average survival after hospitalisation for AHF is 
2 years, with the most vulnerable phase being in the months directly 
after discharge from hospital. Despite significant achievements in 
the treatment of chronic heart failure, all trials targeting AHF with 
short-term in-hospital therapies have had disappointing or at most 
neutral endpoints. Thus, the optimal strategy for improving long-
term outcomes in patients admitted with AHF should be revisited. 
Optimisation, personalisation and continuation of (A)HF treatment 
after hospital discharge seem crucial to achieving the best outcomes. 
This article reviews the principles of optimisation and personalisation 
of AHF treatment during the hospital stay and early outpatient phase.
Triage and the Initial 7-P Evaluation
Patients presenting with (suspected) AHF should undergo rapid triage 
to exclude cardiogenic shock, respiratory failure, myocardial infarction 
and/or arrhythmia and receive the appropriate level of monitoring and 
specific treatments (e.g. pharmacological/mechanical haemodynamic 
support, mechanical ventilation and percutaneous revascularisation).1,6,7 
Moreover, since AHF is a life-threatening condition, initial treatment 
should be started as soon as possible, ideally within 30–60 min after 
hospital admission, as this is associated with better outcomes.6–8 
The initial treatment should then be tailored and optimised according to 
a 7-P evaluation: phenotype, pathophysiology, precipitants, pathology, 
polymorbidity, potential harm and preferences (Figure 1).9
Phenotype
The initial evaluation should include the assessment of the clinical 
phenotype based on symptoms or signs of peripheral hypoperfusion 
(forward failure) and/or systemic congestion (backward failure). 
However, given the limited sensitivity and specificity of clinical 
assessment, additional confirmatory tests may be required, such 
as biomarkers, echocardiography, lung ultrasound or chest X-ray, to 
exclude differential diagnoses. 
The vast majority of AHF patients are well perfused but congested 
(warm-wet), while only a minority are hypoperfused (either cold-wet or 
cold-dry). Hypoperfusion defines cardiogenic shock, the most severe 
clinical presentation of AHF, which accounts for only about 10  % of 
AHF cases. However, the treatment of these patients is often more 
difficult and is associated with 5- to 10-fold higher in-hospital mortality 
compared to normally perfused cases.4,10 Systemic congestion, 
in contrast, is widespread and results from the combination of 
fluid accumulation and redistribution due to a change in vascular 
compliance, with variable proportions according to the clinical 
scenario. Fluid accumulation is found predominantly in cases of acute 
decompensation in chronic heart failure with reduced systolic function, 
while fluid redistribution mostly occurs in new-onset AHF patients with 
preserved systolic function and/or systemic inflammation.
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Pathophysiology 
The second step in the evaluation of AHF patients should focus 
on understanding the leading pathophysiology at play. AHF can 
be a consequence of arrhythmia (with and without atrio- or inter-
ventricular asynchrony), anatomical defects, incompetent valves, 
impaired myocardial contractility, pathological myocardial relaxation, 
hampered ventricular filling and/or excessive cardiac afterload.
As already mentioned, systemic congestion is the central feature 
of AHF and results from the combination of fluid accumulation and 
redistribution induced by neurohumoral activation in the presence of 
cardiac dysfunction.11 Hypoperfusion manifests only in the most severe 
forms of AHF (cardiogenic shock) in the presence of severely impaired 
cardiac output.12 In patients without a previous history of symptomatic 
heart failure (de novo AHF), AHF mostly occurs secondary to a sudden 
deterioration in cardiac function – due to myocardial infarction, severe 
myocarditis or acute valve regurgitation, for example – causing fluid 
redistribution and, in severe forms, peripheral hypoperfusion.3 These 
patients have no or only minor increases in body weight before 
hospital admission. Fluid redistribution and loss due to sweating, 
perspiratio insensibilis or diuretic therapy can cause intravascular 
hypovolaemia and insufficient preload. Consequent sympathetic 
activation induces transient vasoconstriction leading to rapid volume 
displacement from the peripheral and splanchnic venous systems 
to the pulmonary circulation.13,14 A mismatch in the ventricular–
arterial coupling relationship, with increased afterload and decreased 
venous capacitance (increased preload), is the primary alteration in 
hypertensive AHF.15,16
More frequently, AHF consists of acute decompensation of chronic 
heart failure (ADHF) and is caused by progressive fluid accumulation. 
Indeed, persistent neurohumoral activation impairs renal sodium 
excretion, resulting in sodium and then fluid accumulation.17 The 
classical congestive cascade includes subclinical stages characterised 
by increased cardiac filling and venous pressures (haemodynamic 
congestion), followed by redistribution of fluids into the lungs and 
visceral organs (organ congestion) and finally to overt symptoms and 
signs of volume overload (clinical congestion) (Figure 2).11 Although 
clinical and organ congestion usually follows haemodynamic congestion, 
the correlation between hydrostatic pressure and oedema formation is 
weak. Indeed, chronic sodium accumulation in heart failure impairs 
the function of the interstitial glycosaminoglycan network, reducing 
its capacity to buffer additional sodium and maintain low interstitial 
compliance.18 Consequently, interstitial oedema formation may occur 
even in the presence of mildly elevated hydrostatic pressures and 
vascular capacitance may change, causing increased cardiac filling 
pressures without increments in vascular or total body fluid.
Precipitants 
During the third step, triggers of AHF should be identified. AHF 
may be precipitated by several factors that may coexist, such 
as myocardial ischaemia, arrhythmias, infections, uncontrolled 
hypertension and non-compliance with medical prescriptions.2,19,20 
In patients presenting with cardiogenic shock, myocardial infarction 
is by far the most common precipitant.10 The aims when identifying 
precipitants are to detect treatable causes (see below) and provide 
prognostic information. AHF precipitated by an acute coronary 
syndrome or infection is associated with poorer outcomes; whereas 
outcomes tend to be better in AHF precipitated by atrial fibrillation or 
uncontrolled hypertension.2,20,21 
Pathology
The initial treatment of AHF should be started as soon as possible 
according to the clinical presentation. However, understanding of the 
underlying cardiac pathology is essential for providing optimal specific 
therapy and estimating prognosis. For example, giant cell myocarditis 
requires aggressive immunosuppressive therapy, while severe mitral 
regurgitation caused by papillary muscle rupture requires cardiac 
surgery.22 Moreover, end-stage ischaemic heart disease without 
reversible ischaemia and viability may display significantly lower 
recovery potential than peripartum cardiomyopathy.23 Infiltrative heart 
disease may involve other organ systems. Immediate echocardiography 
is recommended in patients presenting with cardiogenic shock or de 
novo AHF.1,6
Polymorbidity
AHF is a syndrome causing organ dysfunction, mainly of the lungs 
and abdominal organs.24–26 Historically, renal and hepatic dysfunctions 
in heart failure have been considered the consequence of visceral 
hypoperfusion, but more recent data have shown that venous 
congestion is the strongest haemodynamic determinant of renal and 
hepatic dysfunction in AHF.27,28 Assessment of organ dysfunction – in 
particular severe renal and kidney failure – as well as other conditions 
causing relative contraindications to diagnostics or treatment – such 
as allergy, pregnancy or active bleeding – are crucial in deciding on 
optimal diagnostic modalities and treatments to be delivered. Rapid 
assessment of frailty is recommended in geriatric patients, since it 
affects overall outcome.29,30 Metabolic disturbances, such as diabetes 
or thyroid disease, anaemia and iron deficiency should be assessed 
and optimised.
Potential Harm
It is crucial to consider the risk of iatrogenic harm associated with 
diagnostics and treatment in every medical decision made. This is 
















































































































































































































Figure 1: The 7-P Initial Evaluation of Acute Heart Failure 
Patients
ADHF = acute decompensated heart failure; AHF = acute heart failure; SCD = sudden cardiac 
death. Adapted from Arrigo et al., 2017.9
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of older, critically-ill, polymorbid subjects.31 For example, indiscriminate 
use of diagnostics (e.g. coronary angiography) and monitoring (e.g. 
pulmonary artery catheter) may expose patients to severe vascular 
or radiological complications; excessive use of inotropic agents in the 
absence of evidence of peripheral hypoperfusion is associated with 
arrhythmia and excess mortality.32,33
Patient Preferences 
The seventh part of the initial evaluation of AHF patients should focus 
on patient preferences and ethical issues. Discussion with the patient (if 
feasible) or with relatives about resuscitation directives and treatment 
options may be time-consuming but is crucial to avoid overtreatment. 
Importantly, long-term options, such as mechanical assist devices or 
transplantation, and the wishes of the patient need to be evaluated early 
rather than late, particularly in AHF patients with the potential for rapid 
deterioration. In the absence of long-term therapeutic options, palliation 
and supportive care should be offered to patients. Relatives should be 
advised of these options if patients are not in a position to consent.34
Treatment at Hospital Admission
Correctly deciding which phenotype/pathophysiology predominates 
is critical in determining which treatment strategy should be used.35 
At hospital admission, AHF patients displaying evidence of congestion 
should receive decongestive treatment such as vasodilators and/or 
diuretics.8,36 While diuretics are mainly used in the presence of fluid 
overload, vasodilators are administered to reduce filling pressures 
in the presence of fluid redistribution and preserved systolic blood 
pressure (>110 mmHg; more cautiously between 90 and 110 mmHg). 
Decongestive therapy should be started as soon as possible and 
titrated according to clinical response.8 Notably, decongestive therapy 
should be continued beyond the improvement of symptoms and 
clinical evidence of organ congestion and maintained until euvolaemia 
is achieved (Figure 2). 
The use of inotropes should be restricted to patients in cardiogenic 
shock due to impaired myocardial contractility, since their inappropriate 
use is associated with increased morbidity and mortality.37 In cases 
of persistent haemodynamic instability despite escalating doses 
of inotropes, mechanical circulatory support such as veno–arterial 
extracorporeal life support and percutaneous left-ventricular assist 
devices should be considered before irreversible organ failure has 
established.7 In severe pulmonary oedema causing hypoxia, high-flow 
oxygen therapy, non-invasive or invasive mechanical ventilation are 
required to ensure oxygenation. 
In addition to decongestive therapy, initial management should include 
specific treatments directed towards decompensation triggers and the 
underlying cardiac disorders. In particular, early coronary angiography 
with revascularisation is recommended in AHF precipitated by acute 
coronary syndrome. Antiarrhythmic treatment and/or electrical 
cardioversion are recommended in AHF precipitated by arrhythmia. 
Rapid initiation of antimicrobial therapy is recommended for AHF 
precipitated by infection/sepsis. Sometimes, percutaneous or surgical 
treatment of structural heart disease is required to achieve durable 
stabilisation. Finally, patients should be maintained on oral disease-
modifying heart failure treatment whenever possible.1
After delivery of the initial treatment, continuous reassessment of 
clinical response and patient allocation in terms of level of care 
should be ensured. The level of care (discharge home, observation, 
ward, telemetry or intensive/intermediate care unit) should integrate 
symptom severity, precipitating factors, haemodynamic and respiratory 
status, the degree of congestion and biomarkers (i.e. natriuretic 
peptides, troponin, renal function and serum lactate) and the patient’s 
general condition. Most patients require hospital admission, about half 
of them to intensive or intermediate care units. Low-risk patients with 
good response to initial therapy may be considered for early discharge.
Treatment Before Discharge and the First 
Outpatient Visit
The optimal time-point for discharging hospitalised AHF patients 
may be difficult to determine due to the need to balance patient 
preferences, healthcare resources and the risk of adverse outcomes. 
Indeed, the risk of death is high during hospitalisation for AHF but is 
even higher during the immediate post-discharge period, which usually 
lasts 2–3 months and is known as the vulnerable phase.38 Therefore, 
optimal transitions of care after hospital discharge may be even 
more important than the delivery of appropriate treatments during 
hospitalisation in reducing adverse outcomes in AHF patients. 
Since the causes of the vulnerable phase remain controversial, 
identification of patients at particularly high risk of adverse outcomes 
after hospital discharge is particularly challenging. A combination of 
pathophysiological disorders and lack of follow up seems to contribute 
to the high mortality and readmission rates observed. Several risk 
scores using multiple clinical variables have been developed, 
but most of them are complex and lack accuracy. Cardiovascular 
biomarkers added to clinical parameters may reveal active sub-clinical 
processes, providing valuable insights into the pathophysiology of 
the vulnerable phase and increasing prognostic accuracy. In the 
future, a comprehensive multi-marker strategy reflecting different 
activated pathways in heart failure (myocardial stress, myocyte 
injury, neurohumoral activation, inflammation, oxidative stress, matrix 
remodelling and systemic congestion) may increase the precision 
of biomarker-guided prognostication.39 Even more importantly, the 
prognostic information derived from a single or multi-marker strategy 
may be translated into therapeutic decisions and personalisation of 
follow up, improving patient outcomes. 
Persistent subclinical congestion may contribute to the high rates of 
death and readmission observed after hospital discharge.40 Indeed, 
despite a global improvement in symptoms during hospital stay, 
a relevant proportion of patients still display markedly elevated 
natriuretic peptides at discharge. This discordance between few 
symptoms and high natriuretic peptide concentrations suggests 
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Figure 2: The Typical Cascade of Systemic Congestion
Modified from Adamson, 2009.49 Published with permission from Springer Nature.
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persistent haemodynamic congestion. Some studies have reported 
an association between pre-discharge levels of natriuretic peptides 
and subsequent risk of death or readmission.41 Based on these data, 
titration of decongestive therapy based only on symptoms and signs 
may be insufficient and should include additional parameters, such as 
biomarkers and/or echocardiography.42,43 
Underutilisation of disease-modifying heart failure therapies such as beta-
blockers, renin–angiotensin system (RAS) inhibitors and mineralocorticoid 
receptor antagonists is prevalent and may further promote adverse 
events after hospital discharge.5,44 Beta-blocker discontinuation during 
hospitalisation is associated with detrimental effects on short-term 
mortality and readmission.45 Very recently, a large propensity score-
matched cohort study showed an association between beta-blocker or 
RAS inhibitor treatment at hospital discharge and a 40–50 % relative risk 
reduction in 90-day mortality.44 It showed an additional 25–50 % relative 
risk reduction with combined beta-blocker and RAS inhibitor therapy 
at hospital discharge compared to either treatment alone.44 The early 
benefits were present in both reduced and preserved ejection fraction 
and persisted at 1-year follow up. In the same study, no significant 
benefit was found with early mineralocorticoid receptor antagonist 
administration. In beta-blocker-intolerant patients, early administration 
of ivabradine might be considered to reduce readmissions during the 
vulnerable phase.46 Current European Society of Cardiology guidelines 
recommend initiation or continuation of disease-modifying heart failure 
therapies during hospitalisation in all AHF patients with reduced ejection 
fraction unless contraindicated.1 Similarly, evaluation of the patient to 
determine whether a cardiac device (implantable cardiac defibrillator 
and/or cardiac resynchronisation therapy) is indicated and, if so, 
planning for its implantation should not be overlooked.
Furthermore, hospital discharge should occur only after precipitating 
factors of AHF have been adequately treated and resolved. This point 
includes revascularisation for myocardial infarction, antiarrhythmic 
therapy for arrhythmias, antimicrobial treatment for infection, 
antihypertensive therapy for hypertension and patient education for 
non-compliance with recommendations. Patient education, home-based 
measurement of body weight and blood pressure, and early contact with 
healthcare providers have all been proposed to reduce readmission 
rates; however, these interventions have produced inconsistent 
results. Early detection of increasing congestion with intrathoracic 
impedance monitoring and implantable haemodynamic monitoring, 
e.g. with the CardioMEMS™ HF System (St Jude Medical), have shown 
promising results in trials but concerns about their cost-effectiveness 
has prevented their widespread introduction in clinical practice.47,48
Finally, hospital discharge should be planned to allow inclusion of 
all patients into a comprehensive, post-discharge care programme. 
If this is not feasible because of limited resources, entry to such a 
programme should be restricted to those with high-risk feature, such 
as markedly elevated natriuretic peptides, abnormal systolic blood 
pressure, persistent hyponatraemia and recurrent readmissions.38 
Outpatient visits to a general practitioner and heart failure clinic should 
be scheduled before hospital discharge to ensure appropriate follow 
up. In our centres, we usually plan a visit to the general practitioner 
within 1 week and a visit to the heart failure clinic within 2–3 weeks 
after discharge.
During early outpatient visits, assessment and optimisation of volume 
status (including the comparison of natriuretic peptide concentration 
with pre-discharge values), up-titration of disease-modifying heart 
failure treatment and evaluation of cardiac device indication should 
be performed. After bridging the vulnerable phase, optimisation of oral 
disease-modifying treatments and regular follow-up visits should be 
continued on an individual basis. 
Conclusion
The initial therapy of AHF should be personalised based on clinical 
phenotype, the pathophysiology at play, precipitants identified and 
underlying cardiac pathology. Particular attention should be given 
to polymorbidity, including organ dysfunction, and the avoidance of 
potential iatrogenic harm. Patient preferences and ethical issues should 
be integrated into the treatment plan at an early phase. Before hospital 
discharge, persistent subclinical congestion and underutilisation of 
disease-modifying heart failure therapies should be addressed and 
appropriate follow up ensured. ฀
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